Drotebanol
Clinical data | |
---|---|
Other names | Drotebanol, Oxymethebanol |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
Melting point | 165 to 167 °C (329 to 333 °F) |
| |
| |
(what is this?) (verify) |
Drotebanol (Oxymethebanol) is a
Sankyo Company in Japan during the 1970s. It is synthesised from thebaine
.
Drotebanol has powerful
antitussive (cough suppressant) effects, and is around 10x more potent than codeine in producing this effect. It also has analgesic effects several times stronger than codeine, but weaker than morphine.[2] In animal studies it was found to be moderately addictive and produced limited physical dependence, but not as severe as that seen with morphine or pethidine.[3]
It was previously marketed for human use under the brand name Metebanyl, although it is now no longer used in medicine.
It is currently a Schedule I Narcotic controlled substance in the United States with a DEA ACSCN of 9335 and an annual aggregate manufacturing quota of zero.
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- PMID 5467447.
- PMID 405065.